Clinical Trial Detail

NCT ID NCT01833169
Title BKM120 for Patients With PI3K-activated Tumors
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Buparlisib

Age Groups: senior adult

Additional content available in CKB BOOST